Pedro C. Barata, MD, MSc, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center and Associate Professor of Hematology and Medical Oncology at Case Western University, said: , describes the unmet need for precision medicine in prostate cancer.
There are many targeted therapies for men with prostate cancer, and a better understanding of how to perform biomarker testing to determine eligibility for treatment. But patient selection remains an important question for oncologists, according to Barata.
Barata hints that the focus of the study will be to determine which patients will do well with a particular treatment. For example, according to Barata, homologous recombination defects may be correlated with response to immune checkpoint inhibitors, which needs to be evaluated in future studies.
Separately, Barata said the efficacy of BiTE therapy and other targeted agents for prostate cancer patients should be investigated.
0:08 | I think the secret here is how you select your patients. There is no doubt that prostate cancer is heterogeneous. Therefore, we can find a subset of patients who would benefit from it. The question is how to choose between them and easily achievable outcomes. In addition to high tumor mutational burden, there is mismatch repair deficiency, lynching, germline, or microsatellite instability. However, this is a small fraction of the population with advanced prostate cancer, again around 3%.
0:42 | In addition, there appears to be an association, for example, between patients with certain normal recombination-deficient genes and their response to immune checkpoint inhibitors. It’s possible and I’m thinking about CDK12 and other things that immune checkpoint inhibitors might play a role. is. And a completely different scenario is, as you know, targeted immunotherapies such as BiTE.